Skip to main content
https://pbs.twimg.com/media/Fn1CZGYWIAcMCRN.jpg
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/gDHbcDpNnT https://t.co/oL0nldQ1fN
Dr. John Cush
Jan-31-2023
×